Sanctura XR (trospium chloride extended-release capsules), made by Indevus Pharmaceuticals, Inc., of Lexington, Mass., has been approved for the once-daily treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and urinary frequency.

The cardinal symptoms of overactive bladder (OAB)—urinary urgency, frequency, and urge urinary incontinence—are not significantly associated with detrusor overactivity after adjustment for other risk factors, a study found.

QUEBEC CITY—Nearly one in 10 Canadian adults suffer from overactive bladder (OAB), according to a population-based survey.

Overactive bladder (OAB) is usually associated with women, but it afflicts nearly one out of every eight American men. Its symptoms can also be confused with those of BPH, resulting in unneeded surgery.

DULOXETINE, a serotonin-noradrenalin reuptake inhibitor, may be an effective treatment for women with symptoms of overactive bladder (OAB). Duloxetine is marketed as Cymbalta for treating depression and diabetic peripheral neuropathy.

OVERACTIVE BLADDER (OAB) symptoms in middle-aged or older men are associated with an increased risk of erectile dysfunction (ED).